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ABSTRACT  
Objective: The aims of the present study were to develop different matrix patches with various ratios of hydrophilic and hydrophobic polymer 
combinations such as ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) and eudragit RL 100 (ERL) and eudragit RS 100 (ERS) containing 
ethinylestradiol and medroxyprogesterone acetate and to perform physicochemical characterization and in vitro permeation studies through rat 
skin. 
Methods: Six formulations (F1 to F6) were developed by varying the concentration of both hydrophilic and hydrophobic polymer and keeping the drug 
load constant. Physical parameters and drug excipient interaction studies were evaluated in all the formulations. In vitro, skin permeation profiles of 
ethinylestradiol and medroxyprogesterone acetate from various formulations were simultaneously characterized in a thermostatically controlled 
modified Franz Diffusion cell. The physicochemical compatibility of the drug and the polymers was studied by differential scanning calorimetry. 
Results: The results suggested no physicochemical incompatibility between the drug and the polymers. In vitro permeation studies were performed 
by using Franz diffusion cells, patches coded as F3 (ethyl cellulose: polyvinylpyrrolidone, 7.5:2.5) and F6 (eudragit RL 100 (ERL) and eudragit RS 
100 (ERS), 8:2) can be chosen for further in vivo studies. The results followed Higuchi kinetics (r = 0.9953-0.9979), and the mechanism of release 
was diffusion mediated. Based on physicochemical and in vitro skin permeation studies of 85.64% (for F3) and 88.62% (for F6) of ethinylestradiol 
and medroxyprogesterone acetate. 
Conclusion: The developed transdermal patches are stable, non-irritating and had increased efficacy of ethinylestradiol and medroxyprogesterone 
acetate and therefore had a good potential for antifertility treatment. 
Keywords: Transdermal, Antifertility, Ethinylestradiol, Medroxyprogesterone acetate, Polyvinylpyrrolidone, Ethylcellulose, Eudragit RL 100 (ERL) 
and eudragit RS 100 (ERS) 




In the early 1960s, shortly after the introduction of oral 
contraceptives, the first case reports appeared describing venous 
thrombosis and pulmonary emboli in women using oral 
contraceptives as a method for birth control. Later, myocardial 
infarction and stroke were also found to be associated with the use of 
oral contraceptives. The absolute risk of venous thrombosis has been 
reported to increase from a baseline risk of less than 1 per 10,000 
women-years to 3 to 4 per 10,000 women-years during use of OCs [1] 
Oral contraceptives containing estrogen-progestin combinations 
have been associated with an increased risk of deep vein thrombosis 
and subsequent pulmonary embolism, collectively referred to as 
venous thromboembolism (VTE) [2-6]. 
A large number of Transdermal Drug Delivery (TDD) systems have 
been widely used to treat a variety of diseases since it has many 
advantages over oral contraceptive pills. TDD systems are able to 
provide the continuous supply of drug through the skin, avoiding 
peaks and troughs as found with oral pills.  
Losses of bioavailability due to first-pass hepatic metabolism and 
enzymatic degradation in the gastrointestinal tract that are seen 
with oral drug administration are avoided, which makes it possible 
to use lower doses of the drug to achieve the therapeutic effect [7]. 
Postmenopausal HRT with oral or transdermal estrogen alone has 
been effective in alleviating vasomotor symptoms of menopause and 
also in reducing cardiovascular mortality risks and osteoporosis, but 
concomitant progestin therapy would protect against endometrial 
hyperplasia and carcinoma without compromising the benefits of 
estrogen therapy [8]. 
Therefore, it was decided to plan formulation and development of 
transdermal patch containing ethinylestradiol and 
medroxyprogesterone acetate using various polymers and 
plasticizers to overcome the side effects associated with oral 
contraceptives pills and have an alternative to the patients suffering 
from daily dosing problems associated with oral contraceptives.  
There are reports describing the use of eudragit RL 100 (ERL) and 
eudragit RS 100 (ERS)transdermal delivery systems as well as other 
dosage forms for controlled release of drugs [9] ERL is freely 
permeable to water, whereas ERS is slightly permeable [10]. These 
transdermal delivery systems are neither extremely hydrophobic 
nor extremely hydrophilic. Therefore, varying the ratio of these 
polymers in the composition of the films provides control of drug 
release characteristics [11].  
The aims of the present study were to develop different matrix 
patches with various ratios of hydrophilic and hydrophobic polymer 
combinations such as ethyl cellulose (EC) and polyvinylpyrrolidone 
(PVP) and eudragit RL 100 (ERL) and eudragit RS 100 (ERS) 
containing ethinylestradiol and medroxyprogesterone acetate and to 
perform physicochemical characterization and in vitro permeation 
studies through rat skin. The purpose was to provide the delivery of 
the drug at a controlled rate across intact skin to improve 
bioavailability and hypertension control for the longer period from 
transdermal patches. 
MATERIALS AND METHODS 
Materials 
Ethinylestradiol was obtained as a gift sample from Cipla 
pharmaceuticals, Ltd., Mumbai and medroxyprogesterone acetate 
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was obtained from Tokyo Chemical Industry Co., Ltd, Japan. Eudragit 
RL 100 (ERL) and eudragit RS 100 (ERS), Hydroxypropyl methyl 
cellulose (HPMC), ethylcellulose (EC) and polyvinylpyrrolidone 
(PVP) were obtained from Central Drug House Pvt. Ltd., New Delhi. 
Other materials used in the study (sodium chloride, disodium 
hydrogen phosphate, potassium dihydrogen phosphate etc) were 
purchased from Central Drug House Pvt. Ltd., New Delhi and were of 
analytical grade. Double Distilled water was used throughout the 
study. Other materials used in the study (chloroform, sodium 
hydroxide, phosphoric acid, diethyl ether, were of analytical grade. 
Double-distilled water was used throughout the study. 
Investigation of physicochemical compatibility of drug and 
polymer 
The physicochemical compatibility between ethinylestradiol and 
medroxyprogesterone acetate and polymers used in the patches was 
studied by using differential scanning calorimetry (DSC, Perkin-
Elmer–Pyris 6 DSC, Salem, MA). In DSC analysis, the samples were 
weighed (5 mg), hermetically sealed in flat-bottom aluminum pans, 
and heated over a temperature range of 50 to 250 °C in an 
atmosphere of nitrogen (20 ml/min) at a constant increasing rate of 
10 °C/min. The thermograms obtained for ethinylestradiol and 
medroxyprogesterone acetate, polymers, and physical mixtures of 
ethinylestradiol and medroxyprogesterone acetate with polymers 
were compared. 
The infrared (IR) spectra were recorded using an FTIR 
spectrophotometer (FTIP-800, Biorad, Munich, Germany) by the KBr 
pellet method and spectra were recorded in the wavelength region 
between 4000 and 400 cm–1. The spectra obtained for 
ethinylestradiol and medroxyprogesterone acetate polymers and 
physical mixtures of ethinylestradiol and medroxyprogesterone 
acetate with polymers were compared. 
Preparation of transdermal films 
The matrix-type transdermal patches containing ethinylestradiol 
and medroxyprogesterone acetate were prepared using different 
ratios of EC: PVP and ERL 100:ERS 100 (table 1). The polymers in 
different ratios were increased to a total weight of 400 mg and 
dissolved in chloroform. Ethinylestradiol and medroxyprogesterone 
acetate was added slowly to the polymer solution and mixed 
thoroughly to obtain a uniform solution. Di-n-butyl-phthalate was 
used as a plasticizer. The polymeric solution of drug was poured 
onto the mercury surface (25 cm2) and dried at room temperature in 
a dust-free environment. After 24 h, the films were cut into a 5 cm2
 
 
piece, and a backing membrane of polypropylene film was glued on. 
The transdermal films were stored in a desiccator until further use. 
Table 1: Composition of ethinylestradiol and medroxyprogesterone acetate transdermal Drug Delivery systems 
S. No. Ingredients Formulation codes 
F1 F2 F3 F4 F5 F6 
Ethinylestradiol (mg) 0.35 0.35 0.35 0.35 0.35 0.35 
Medroxyprgesterone acetate (mg) 2.14 2.14 2.14 2.14 2.14 2.14 
1 Ratio of ethylcellulose (EC): polyvinylpyrroplidone (PVP) 9:1 8:2 7.5:2.5 - - - 
2 Ratio of eudragit RL 100 (ERL): eudragit RS 100 (ERS) - - - 5:5 7:3 8:2 
3 Propylene glycol (% w/w) 30 30 30 30 30 30 
4 DMSO 7 7 7 7 7 7 
EC: ethyl cellulose, PVP: polyvinylpyrrolidone, HPMC: hydroxypropyls methylcellulose, PG: propylene Glycol, DMSO: Dimethyl sulfoxide, all values 
are expressed as mean±SD (n=10) 
 
Evaluation of physicochemical properties of patches 
Weight variation 
Weight variation was studied by individually weighing 10 randomly 
selected patches. Such determination was performed for each 
formulation [12]. 
Drug content 
The patch (1 cm2
Flatness 
) was cut and added to a beaker containing 100 ml of 
phosphate buffered pH 7.4. The medium was stirred (500 rpm) with 
teflon coated magnetic bead for 5 h. The contents were filtered using 
whatman filter paper, and the filtrate was analyzed by U. V. 
spectrophotometer at 280 nm for the drug content against the blank 
solution [12, 24]. 
Three longitudinal strips were cut out from each film: 1 from the 
center, 1 from the left side, and 1 from the right side. The length of 
each strip was measured and the variation in length because of non-
uniformity in flatness was measured by determining percent 
constriction, with 0% constriction equivalent to 100% flatness [12] 
Folding endurance 
Folding endurance was determined by repeatedly folding the film at 
the same place until it broke. The number of times the film could be 
folded at the same place without breaking was the folding 
endurance value [12, 24]. 
Percentage of moisture content 
The films were weighed individually and kept in a desiccator 
containing activated silica at room temperature for 24 h. Individual 
films were weighed repeatedly until they showed a constant weight. 
The percentage of moisture content was calculated as the difference 
between the initial and final weight with respect to final weight [13] 
Percentage of moisture content = X-Y/Y × 100 
Where, X = initial weight, Y = final weight. 
Percentage of moisture uptake 
A weighed film kept in a desiccator at room temperature for 24 h 
was taken out and exposed to 84% relative humidity (a saturated 
solution of aluminum chloride) in a desiccator until a constant 
weight for the film was obtained. The percentage of moisture uptake 
was calculated as the difference between final and initial weight 
with respect to initial weight [14]. 
Percentage of moisture uptake = X-Y/Y × 100 
Where, X = initial weight, Y = final weight. 
In vitro skin permeation studies 
The in vitro release was carried out with the semipermeable 
membrane using open-ended cylinder. The cylinder consists of two 
chambers, the donor and the receptor compartment. The donor 
compartment was open at the top and was exposed to an 
atmosphere. The temperature was maintained at 37±0.5 °C and 
receptor compartment was provided with sampling port. The 
diffusion medium used was phosphate buffer (pH 7.4). The drug-
containing patch with support of backing membrane was kept in the 
donor compartment and it was separated from the receptor 
compartment by the semipermeable membrane. The semipermeable 
membrane was previously soaked for 24 h in phosphate buffer (pH 7.4) 
the receptor compartment containing 300 ml phosphate buffer (pH 
7.4) in a beaker was maintained at 37±0.5 °C and stirred at 50 rpm 
with magnetic beads operated by a magnetic stirrer. A sample of 1 
ml was withdrawn at predetermined time intervals and replaced 
with fresh buffer. The concentration of drug was determined by 
spectrophotometrically at 280 nm. The cumulative amounts of drug 
permeated per square centimeter of patches were plotted against 
time [15, 25]. 
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Simultaneous spectrophotometric determination of 
ethinylestradiol and medroxyprogesterone acetate  
Ethinylestradiol absorbs at λmax of Medroxyprogesterone acetate 
and vice versa. Thus, a simple spectrophotometric method using no 
prior separation has been developed for the analysis of 
ethinylestradiol and Medroxyprogesterone acetate in phosphate 
buffer (pH7.4) by Vierordt's equation in our laboratory (15, 25). 
Ex vivo skin permeation studies  
The in vitro skin permeation studies were carried out using the 
dorsal section of full thickness skin from wistar rats weighing 
between (200-250 g) hairs were removed by shaving from the 
dorsal area one day before the test. All the experimental procedures 
were approved by the Institutional Animal Ethics Committee (IAEC). 
All the experimental procedures were carried out accordance with 
the committee for the purpose of control and supervision of 
experiment on animal guidelines (129/2013/CPCSEA). Wistar rat’s 
hairs were removed by shaving from the dorsal area one day before 
the test. The transdermal patches were firmly pressed on the centre 
of the rat skin. Once adhesion to the skin surface had been 
confirmed, the skin was quickly mounted on the diffusion tube 
which acted as the donor compartment. 100 ml of phosphate buffer 
of pH 7.4 taken in a beaker, which acted as the receptor 
compartment to maintain the sink condition. The donor 
compartment was kept in contact with the receptor compartment 
and the receptor compartment was stirred magnetically during the 
study [15]. After every 1 h sample (1 ml) was withdrawn at 
predetermined time intervals and replaced with fresh buffer. The 
concentration of drug was determined by U. V. spectro-
photometrically at 280 nm [15]. 
RESULTS AND DISCUSSION 
Investigation of physicochemical compatibility of drug and 
polymer 
The physicochemical compatibility between the drugs and polymers 
used in the patches was studied by using differential scanning 
calorimetry (DSC). The sample was heated between 30 °C and 300 °C 
at the rate of 10 °C/min in an atmosphere of nitrogen (20 ml/min). 
The thermograms obtained for the drug, polymers, physical mixture 
of drugs with polymers and formulation (patch) were compared. 
The DSC results suggest that the drug and polymers are compatible 
as found in fig. 1. Wade and Weller reported that ethylcellulose (EC), 
polyvinylpyrrolidone (PVP), eudragit RL 100 (ERL), eudragit RS 100 
(ERS), and other common polymers are popular in controlled-and 
sustained release matrix-type patches because of their compatibility 
with several drugs [16]. 
 
 
Fig. 1: DSC thermograms of drugs, polymers, and the physical 
mixtures. Cr indicates drug substances 
 
Physicochemical characterization of patches 
The results of the physicochemical characterization of the patches 
are shown in table 2. The weights ranged between 26.43 mg and 
26.88 mg, which indicates that different batches’ patch weights were 
relatively similar. Good uniformity of drug content among the 
batches was observed with all formulations and ranged from 
96.26% to 96.87%. The results indicate that the process employed 
to prepare patches in this study was capable of producing patches 
with uniform drug content and minimal patch variability. The 
flatness study showed that all the formulations had the same strip 
length before and after their cuts, indicating 100% flatness. 
Thus, no amount of constriction was observed; all patches had a 
smooth, flat surface; and that smooth surface could be maintained 
when the patch was applied to the skin. Folding endurance test 
results indicated that the patches would not break and would 
maintain their integrity with general skin folding when applied. 
Moisture content and moisture uptake studies indicated that the 
increase in the concentration of hydrophilic polymer was directly 
proportional to the increase in moisture content and moisture uptake 
of the patches. The moisture content of the prepared formulations was 
low, which could help the formulations remain stable and reduce 
brittleness during long-term storage. The moisture uptake of the 
formulations was also low, which could protect the formulations from 
microbial contamination and reduce bulkiness [17, 24]. 
 
 
Fig. 2: Release profiles of ethinylestradiol and medroxyprogesterone acetate from formulations F1-F6. All values are expressed as 
mean±SD (n=3) 
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1 F1 0.026±0.002  2.134±0.010  2.174±0.023 96.54±0.36  105±2.6  26.43±0.16  15.13±0.23  2.574±0.023  0.01680±0.002  
2 F2 0.026±0.006  2.283±0.013  2.321±0.011  96.55±0.24  95±2.4  26.87±0.18  14.96±0.35  2.321±0.011  0.01676±0.005  
3 F3 0.025±0.005  2.106±0.024  2.643±0.021  96.87±0.28  102±5.6  26.50±0.16  15.44±0.17  2.643±0.021  0.01692±0.006  
4 F4 0.025±0.004  2.328±0.021  2.232±0.016  98.45±0.27  110±4.9  26.22±0.17  15.36±0.27  2.632±0.016  0.01706±0.003  
5 F5 0.024±0.002  2.432±0.010  2.528±0.015  97.29±0.75  119±5.2  25.95±0.26  15.58±0.12  2.528±0.015  0.01704±0.002  
6 F6 0.026±0.003  2.514±0.021  2.628±0.015  96.26±0.84  111±3.7  26.88±0.14  14.32±0.27  2.316±0.011  0.01694±0.005  
*All values are expressed as mean±SD (n = 10). 
 
 
Fig. 3: In vitro skin permeation profile of ethinylestradiol and medroxyprogesterone acetate from transdermal patches with different 
proportions of Ethylcellulose: polyvinylpyrrolidone, data are mean±SE (n=6) 
 
 
Fig. 4: In vitro skin permeation profile of ethinylestradiol and medroxyprogesterone acetate from transdermal patches with different 
proportions of ERL 100: ERS 100 Data are mean±SE (n=6) 
 
In vitro skin permeation studies 
The in vitro release profile is an important tool that predicts in 
advance how a drug will behave in vivo [18]. The results of in vitro 
skin permeation studies of ethinylestradiol and medroxy-
progesterone acetate from transdermal patches are shown in fig. 2, 
fig. 3 and fig. 4. The cumulative amount of drug released from 
formulations (1 cm2) F3 and F6 was high when compared with 
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release from other formulations. When the cumulative amount of 
drug permeated per square centimeter of patches through rat skin 
was plotted against time, the permeation profiles of the drug 
followed mixed zero-order/first-order kinetics. The in vitro release 
profiles of the formulations did not fit into zero-order kinetics (r 2 = 
0.9206-0.9282) or first-order kinetics (r 2 = 0.6615-0.6782). 
However, the release profile of the formulated patches followed 
Higuchi’s equation (r 2 = 0.9953-0.9979), which indicates that the 
permeation of the drug from the patches was governed by a 
diffusion mechanism. Since many release processes can be 
represented by a coupling of a Fickian and non-Fickian mechanism, 
Ritger and Peppas introduced the power law equation Mt/M∞ = Ktn 
to characterize the controlled-release behavior of a drug from 
polymer matrices [19]. The value of n can be calculated from the 
slope of In Mt/M∞ vs in t and can be indicative of the operating 
release mechanism. The n values (0.5022<n>0.5268) obtained by 
this equation indicated that the amount of drug released by Fickian 
diffusion predominated with all formulations. In this context, the 
results obtained from the Fickian mechanism support the results of 
Higuchi’s equation and the theory that the patches release the drug 
by a diffusion-dominated mechanism. 
The in vitro permeation experiment indicated that when the 
hydrophilic polymer concentration increased, the amount of drug 
permeation increased. As described by Rao and Diwan, initial rapid 
dissolution of the hydrophilic polymers occurs when the patch is in 
contact with the hydrated skin, resulting in the accumulation of high 
amounts of the drug on the skin surface and thus leading to the 
saturation of the skin with drug molecules at all times [20, 22]. 
Unlike the formulations F1, F2, F4, and F5, the formulations F3 and 
F6 achieved a high cumulative amount of drug permeation at the 
end of 24 h. The F3 and F6 formulations were found to have similar 
permeability coefficients and the highest levels of release. Based on 
physicochemical and in vitro release experiments, F3 and F6 were 
chosen for further in vivo studies. 
 
Table 3: Regression coefficient (r2)
Formulation code  
 values of kinetic model of formulation F1-F6 
Zero order  
regression value (R2
First order  
)  regression value  
Higuchi  
regression value  
Koresmeyar peppas (slope)  
F1 0.987  0.936  0.923  0.985  
F2 0.932  0.934  0.923  1.206  
F3 0.938  0.931  0.937  1.022  
F4 0.936  0.935  0.922  1.024  
F5 0.949  0.934  0.944  1.023  
F6 0.934  0.931  0.926  1.024  
It is evident that all the formulations F1-F6 followed Higuchi kinetics, as the regression coefficients (r2) values (table 3) for the release of both 
ethinylestradiol and medroxyprogesterone acetate are closer to 1 and more than the (r2
 
Skin irritation test 
) values obtained after treating the data through zero order 
or first order kinetics. 
The skin irritation test of the transdermal formulations F3 and F6 
showed a skin irritation score (erythema and edema) of less than 2 
(table 4). According to Draize et al., compounds producing scores of 
2 or less are considered negative (no skin irritation) [21, 23, 26]. 
Hence, the developed transdermal formulations are free of skin 
irritation.
 
Table 4: Visual scores of skin irritation amongst various groups 
Group I II III IV 
Control (No treatment) Blank (Blank patch) Medicated (Medicated patch) Formalin (0.8% aq. Solution) 
Eythema 0.00±0.00 1.167±0.408** 1.50±0.548** 3.333±0.516 
Edema 0.00±0.00 1.167±0.753** 1.333±0.816** 3.167±0.753 
All values are reported as (mean value±SEM) (n=6), **
 
represents P<0.01 (very significant) in comparison to group IV 
CONCLUSION 
The ethinylestradiol and medroxyprogesterone acetate transdermal 
patches developed in this study have great utility and are a viable option 
for effective and controlled management of antifertility. However, 
pharmacodynamics and pharmacokinetic evaluation of these systems in 
human volunteers is necessary to confirm these findings. 
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